BERLIN and NEW YORK, April 26, 2022 /PRNewswire/ —
tenacio, whose mission is to improve clinical outcomes for cardiovascular patients and to reduce healthcare costs, has published an in-silico study with more than 50,000 patients demonstrating very significant expected outcome improvements in a highly respected peer-reviewed journal.
Atrial fibrillation (AF) is the most common heart rhythm disorder, affecting more than 17 million patients in the US and Europe alone. It can result in strokes, hospitalizations, and pre-mature death. Current treatment guidelines recommend using risk tools to optimize treatments of AF patients. Professor Keith AA Fox from University of Edinburgh, and one of the researchers involved in this study said: “There is still a significant gap between current treatment and optimal treatment according to clinical guidelines. We need easy-to-use tools for physicians to support and optimize their treatment decisions”.
tenacio has developed OptiCorTM a digital healthcare solution to address this unmet need. Its proprietary risk prediction algorithm combines precision medicine and curated clinical evidence and guideline-based patient treatment recommendations.
Clinical Researchers recently investigated the improvement potential of using this device for treatment optimization. 52,018 patients from a global registry were included in this analysis. The outcome events of mortality, stroke, and bleeding were analyzed, comparing the expected rates when using OptiCorTM with observed rates in real clinical practice over a two-year period. The study showed that mortality could be reduced by 23%, stroke by 24% and bleeding by 14%.
tenacio’s co-founder and CEO Dr. Georg van Husen commented: “The effect size demonstrates the significant improvement potential in preventing devastating and deadly events in patients with atrial fibrillation. We are committed to translate these findings into clinical practice together with our clinical partners.”
The manuscript can be accessed at https://doi.org/10.1093/ehjdh/ztac011
About tenacio
View original content to download multimedia:https://www.prnewswire.com/news-releases/digital-cardiovascular-care-company-tenacio-announces-publication-of-benefit-analysis-in-european-heart-journal-digital-health-301532907.html
SOURCE tenac.io, Inc.
NEWTOWN, Pa., Dec. 22, 2024 /PRNewswire/ -- The law firm of Edelson Lechtzin LLP is…
Miami, Florida--(Newsfile Corp. - December 21, 2024) - Amid the vibrant backdrop of Art Basel…
Daily Fit Notes, founded by Justin Brey in New York, launches a text-based subscription fitness…
MT. STERLING, Ohio, Dec. 20, 2024 /PRNewswire/ -- WillowWood, a global leader in prosthetic solutions,…
TORONTO, ON / ACCESSWIRE / December 20, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma"…
Toronto, Ontario--(Newsfile Corp. - December 20, 2024) - Glow Lifetech Corp. (CSE: GLOW) (OTC Pink:…